Business Context and Reporting Period
Company: Jin Medical International Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2026 (Specifically dated September 8, 2026)
Context: The Company entered into a material definitive agreement to acquire contractual control over Huaxia Qiying (the "Target") and related entities via a Variable Interest Entity (VIE) structure. The Target holds ginseng-related biological assets and fermentation technology but does not currently operate an established commercial business. This acquisition aligns with the Company's strategy to expand from elderly-care products into a broader integrated senior-health platform.
Key Financial Metrics and Transaction Value
Transaction Consideration: The aggregate consideration for the acquisition is US$159,415,729.
Payment Method: Primarily through the issuance of 71,282,488 Class A ordinary shares (par value US$0.001) at closing.
Advisory Fees: A financial advisory fee of US$15,941,572.90 (10% of transaction value) is payable in shares. This equates to 8,479,560 Class A ordinary shares valued at US$1.88 per share.
Asset Transfers:
- HTFX Investment Assets: US$4,194,167
- Changzhou Zhongjin Investment Assets: RMB109,380,958
- Taizhou Zhongjin Investment Assets: RMB9,698,760
- Zhongjin Kangma Equity/Debt: 80% equity interest (RMB8,000,000 registered capital) and RMB18,000,000 receivable.
Material Changes and Transaction Structure
The filing details a significant structural change involving the acquisition of assets and contractual control rather than direct equity ownership of the Target.
- VIE Structure: The Company, through Erhua Med, will obtain contractual control and economic benefits of Huaxia Qiying via VIE agreements with Chenglan Kangxu and the Seller Controlling Person. Legal title to equity interests will not be acquired solely through these agreements.
- Asset Composition: The Target's assets consist principally of ginseng-related biological resources, research results, and the KB-120 multi-stage fermentation technology platform.
- Contingent Consideration: If the transfer of the 80% equity interest in Zhongjin Kangma is not completed by October 31, 2026, the Company will issue 622,123 Class A ordinary shares as replacement consideration.
Guidance, Risks, and Conditions
Closing Conditions: The transaction is subject to customary conditions, including:
- Absence of governmental prohibition or unresolved PRC legal issues.
- Execution of VIE agreements and ancillary transfer documents.
- Completion of Nasdaq notification processes and reliance on home-country practice.
- Satisfactory completion of legal, financial, and regulatory due diligence.
- Absence of a Material Adverse Effect regarding the Target.
- Regulatory Risk: The transaction relies on PRC law permitting the VIE structure and the exercise of purchase options.
- Commercialization Risk: The Target does not currently operate an established commercial business; value is derived from future research-result commercialization.
- Share Issuance: Significant dilution may occur due to the issuance of over 79 million shares (acquisition + advisory fees) if the transaction closes.
Investor Verification Checklist
- Valuation Justification: Verify the rationale for the US$159.4 million valuation of a Target with no established commercial business.
- VIE Legal Viability: Confirm the enforceability of the VIE agreements under current PRC regulations and the absence of legal impediments to closing.
- Dilution Impact: Assess the impact of issuing approximately 79.76 million new shares on existing shareholders' equity.
- Advisory Fee Structure: Review the 10% advisory fee paid in shares and the designation of shares to third parties (Quinnet Section Limited).
- Asset Transfer Timeline: Monitor the completion of the Zhongjin Kangma equity transfer by the October 31, 2026 deadline to avoid contingent share issuance.